SCS Capital Management’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.09M Hold
197,998
– – 0.04% 161
2026
Q2
$5.09M Hold
197,998
– – 0.05% 155
2026
Q1
$3.8M Hold
197,998
– – 0.04% 162
2025
Q4
$3.27M Hold
197,998
– – 0.03% 175
2025
Q3
$2.87M Hold
197,998
– – 0.03% 184
2025
Q2
$2.77M Hold
197,998
– – 0.03% 194
2025
Q1
$2.69M Buy
+197,998
New +$3.79M 0.03% 172

Other funds holding DNLI

SCS Capital Management's DNLI Position: Q3 2026 in Review

SCS Capital Management held its Denali Therapeutics (DNLI) position steady in Q3 2026 at 197,998 shares worth $4.09M. The position accounts for 0.04% of the portfolio, ranked #161.

SCS Capital Management first reported a position in DNLI in Q1 2025 and has held it in 7 quarters since. The position peaked at $5.09M in Q2 2026. 287 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • SCS Capital Management held 197,998 shares of Denali Therapeutics worth $4.09M as of Q3 2026.
  • SCS Capital Management left its Denali Therapeutics share count unchanged in Q3 2026.
  • Denali Therapeutics made up 0.04% of SCS Capital Management's portfolio in Q3 2026, its #161 holding.
  • SCS Capital Management first reported a position in Denali Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • SCS Capital Management's Denali Therapeutics position peaked at $5.09M in Q2 2026.
  • 287 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on SCS Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.